Last reviewed · How we verify
Colchicine (for 3 months)
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators.
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators. Used for Acute gout flares, Familial Mediterranean fever, Pericarditis.
At a glance
| Generic name | Colchicine (for 3 months) |
|---|---|
| Sponsor | Azienda Sanitaria Locale 3, Torino |
| Drug class | Microtubule inhibitor / Anti-inflammatory agent |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Colchicine binds to β-tubulin and prevents microtubule assembly, which disrupts cell division and inflammatory cell movement. This mechanism reduces the recruitment of neutrophils and other immune cells to sites of inflammation, and decreases the production of pro-inflammatory cytokines such as IL-1β and TNF-α. The anti-inflammatory effect makes it useful in conditions characterized by acute inflammatory flares.
Approved indications
- Acute gout flares
- Familial Mediterranean fever
- Pericarditis
- Behçet's disease
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Myopathy
- Peripheral neuropathy
- Leukopenia
Key clinical trials
- Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation (PHASE2)
- Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke (PHASE4)
- A Randomized Multicenter Study for Isolated Skin Vasculitis (PHASE2)
- Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout (PHASE4)
- is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever (NA)
- Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise (NA)
- Anti-inflammatory Therapy for Recurrent In-stent Restenosis (PHASE4)
- Oral Colchicine in Argentina to Prevent Restenosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colchicine (for 3 months) CI brief — competitive landscape report
- Colchicine (for 3 months) updates RSS · CI watch RSS
- Azienda Sanitaria Locale 3, Torino portfolio CI